Effect of Cisplatin/Curcumin-Loaded Polycaprolactone Nanoparticles on Oral Carcinoma Cells

Abstract:

This work aimed to investigate the effect of cisplatin (CDDP)/curcumin (Cur)-loaded polycaprolactone nanoparticles (PCL-NPs) on an oral epidermal carcinoma cell line. PCL-NPs were fabricated using nanoprecipitation method employing poly(vinyl alcohol) and polysorbate 80 as stabilizers. Two anticancer compounds, CDDP and Cur, were incorporated into the PCL-NPs by entrapment technique. The physical characteristics of the NPs were evaluated. The presence of the drugs on the NPs was ascertained using Attenuated total reflection Fourier-transformed infrared (ATR-FTIR) spectroscopy, and the drug content was quantified by indirect method using ultraviolet spectroscopy and inductive coupled plasma-mass spectroscopy. The cytotoxic effect was demonstrated using MTT assay and the synergistic effect of both drugs was calculated by the combination index method using CompuSyn^® software. The findings revealed that the PCL-NPs were less than 300 nm with narrow size distribution. The appropriate drug concentration for drug loading was 0.12 mg/mL of Cur and 0.02 mg/mL of CDDP, providing approximately 70% and 80% loading efficacy, respectively. The improved anticancer effect was observed in the cells treated with mixture of the drugs and the NPs loaded with dual drugs. Above all, CDDP/Cur-loaded PCL-NPs were successfully prepared. The delivery system exhibited good anticancer effect against oral cancer cells which may be attributed to the synergism effect of CDDP and Cur loaded on the NPs.

• Periodical: Key Engineering Materials (Volume 901)
• Pages: 123-128
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.901.123
• Online since: October 2021
• Authors: Chaiyakarn Pornpitchanarong*, Suwannee Panomsuk, Theerada Taesotikul
• Keywords: Cisplatin, Curcumin, Oral Cancer, Polycaprolactone Nanoparticles

References

[1] D. E. Johnson, B. Burtness, C. R. Leemans, V. W. Y. Lui, J. E. Bauman, J. R. Grandis, Head and neck squamous cell carcinoma, Nature Reviews Disease Primers. 6 (2020) 92.

DOI: 10.1038/s41572-020-00224-3

[2] K. P. Pendleton, J. R. Grandis, Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck, Clin Med Insights Ther. 2013 (2013).

DOI: 10.4137/cmt.s10409

[3] S. Dasari, P. B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol. 740 (2014) 364-378.

DOI: 10.1016/j.ejphar.2014.07.025

[4] M. Ebrahimifar, M. Hasanzadegan Roudsari, S. M. Kazemi, H. Ebrahimi Shahmabadi, L. Kanaani, S. A. Alavi, et al., Enhancing Effects of Curcumin on Cytotoxicity of Paclitaxel, Methotrexate and Vincristine in Gastric Cancer Cells, Asian Pac J Cancer Prev. 18 (2017) 65-68.

[5] B. L. Tan, M. E. Norhaizan, Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer, Molecules. 24 (2019).

DOI: 10.3390/molecules24142527

[6] R. Wilken, M. S. Veena, M. B. Wang, E. S. Srivatsan, Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma, Molecular Cancer. 10 (2011) 1-19.

DOI: 10.1186/1476-4598-10-12

[7] W. Badri, K. Miladi, S. Robin, C. Viennet, Q. A. Nazari, G. Agusti, et al., Polycaprolactone Based Nanoparticles Loaded with Indomethacin for Anti-Inflammatory Therapy: From Preparation to Ex Vivo Study, Pharm Res. 34 (2017) 1773-1783.

DOI: 10.1007/s11095-017-2166-7

[8] T. C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res. 70 (2010) 440-446.

DOI: 10.1158/0008-5472.can-09-1947

[9] Y. Huang, S. Sun, C. Huang, Q. Yong, T. Elder, M. Tu, Stimulation and inhibition of enzymatic hydrolysis by organosolv lignins as determined by zeta potential and hydrophobicity, Biotechnology for Biofuels. 10 (2017) 1-11.

DOI: 10.1186/s13068-017-0853-6

[10] N. G. Vallianou, A. Evangelopoulos, N. Schizas, C. Kazazis, Potential anticancer properties and mechanisms of action of curcumin, Anticancer Res. 35 (2015) 645-651.